Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HC 5404

Next Previous
Search
Drug Profile

HC 5404

Alternative Names: HC-5404; HC-5404-FU; PERK inhibitor - HiberCell

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HiberCell
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EIF-2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Renal cell carcinoma; Small cell lung cancer

Most Recent Events

  • 17 Dec 2024 Chemical structure information added.
  • 31 May 2024 Adverse events, efficacy and pharmacokinetics data from a phase-I trial in Solid tumours presented at the presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 09 Apr 2024 Phase-I development is ongoing in Breast-cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (HiberCell pipeline; April 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top